Recent advances in the management of optic neuritis. by Kortvelesy, S
Recent Advances in the
Management of Optic Neuritis
Scott Kortvelesy MD
Optic neuritis is an acute demyelinating disease of the optic nerve.
The typical patient reports a unilateral reduction in vision progress
ing over several days, commonly associated with pain on eye
movement. The visual acuity usually “bottoms out” at 7-14 days and
then slowly recovers over 6-12 weeks. Permanent reduction of
visual acuity and even blindness may occur. Diagnosis is based on
the patient history, reduced visual acuity, color vision and visual
field, as well as the presence ofan afferent pupillary defect (Marcus
Gunn pupil). Disc swelling is variable. Although MRI may visual
ize a signal abnormality along the optic nerve (see Fig. 1), it is
usually not necessary to make the diagnosis.
While it may be an isolated event, optic neuritis takes much larger
significance from its association with multiple sclerosis. Long term
studies have shown that 15 years after an attack of optic neuritis,
34% of men and 74% of women will develop multiple sclerosis.1
The Optic Neuritis Treatment Trial is a national collaborative
study funded by the National Eye Institute of Bethesda, Maryland.
It is a randomized, placebo controlled trial of 457 patients to look at
the natural history of no treatment versus steroid treatment of optic
neuritis.2
The mean age of patients recruited for the study was 32 years, and
77% were women.3 The optic nerve was ophthalmoscopically
normal in 65% and edematous in 35%. The visual loss was associ
ated with pain in 92% of cases. Magnetic resonance imaging
showed changes “consistent with” demyelinating disease in 49% of
patients. As expected, nearly all of the patients (98%) had visual
field defects in the affected eye, but the “unaffected” fellow eye had
a surprisingly high rate of abnormal visual fields at 48%.
The optic neuritis treatment trial randomized patients with acute
optic neuritis to one of three groups; 1) Prednisone 1 mg/kg/day for
14 days, 2) Intravenous methylprednisolone 1 gm/day for 3 days
followed by 11 days of oral prednisone at 1 mg/kg/day, or 3) oral
placebo for 14 days. Patients were then followed for changes in
visual acuity, color vision, visual field and contrast sensitivity.
The study concluded that while treatment with intravenous meth
ylprednisolone hastened the visual recovery, there was no long-
term visual benefit over placebo. Surprisingly, the study also found
that those patients treated with oral prednisone alone had an
increased risk ofrecurrent optic neuritis. Therefore, treatment of the
demyelinating form of optic neuritis with prednisone alone is utit
recommended.
Two year follow-up data indicated that those patients with signal
abnormalities on brain MRI had a much higher risk for the devel
opment of definite multiple sclerosis.4By three years, the risk for
definite MS was 43% for those who had three or more lesions on the
baseline brain MRI.° This compared with a 28% risk among those
with one or two signal abnormalities and only a 9% risk in those
with normal scans or scans with nonspecific changes at baseline.
The two year data also strongly suggested that intravenous methyl
prednisolone reduced the rate of development of multiple sclerosis
compared with placebo (7.5% versus 16.7%). Unfortunately this
protective effect of methylprednisolone is temporary. Preliminary
four year follow-up data showed that clinically definite multiple
sclerosis developed in 25% of those treated with intravenous
methylprednisolone versus 27% of those treated with placebo.
Based on these results and in view of the availability of new
medications such as Betaseron and Avonex for treatment of mul
tiple sclerosis, it seems reasonable to recommend an MRI scan of
the brain on any new patient with acute optic neuritis. If the MM
shows evidence of demyelinating disease or if the patient needs or
desires a quicker recovery of vision, then intravenous methylpred
nisolone should be offered.
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